Global Cancer Immunotherapies Market 2016-2020


#715922

121pages

Technavio

$ 2500

In Stock

About Cancer Immunotherapies

Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs market.

Technavios analysts forecast the global cancer immunotherapies market to grow at a CAGR of 15.17% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global cancer immunotherapies market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cancer immunotherapies used to treat cancer.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Cancer Immunotherapies Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Amgen
Bristol-Myers Squibb
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Takeda Pharmaceuticals

Other prominent vendors
AbbVie
ADC Therapeutics
Agensys
Astellas
AstraZeneca
Bayer
Biogen
Biotech Pharmaceutical
Boehringer-Ingelheim
Celgene
Celldex Therapeutics
Chugai Pharmaceutical
CTI Biopharma
Daiichi Sankyo
Eli Lilly
Fortress Biotech
Genmab
Immunomedics
Intas Pharmaceuticals
Janssen Biotech
Kyowa Hakko Kirin
MedImmune
Morphotek
Neovii Biotech
Novartis
OncoMed Pharmaceuticals
Pfizer
Sanofi
Seattle Genetics
Spectrum Pharmaceuticals
TG Therapeutics
XBiotech

Market driver
Increase in demand for cancer monoclonal antibodies
For a full, detailed list, view our report

Market challenge
Patent expiry of top-selling drugs
For a full, detailed list, view our report

Market trend
Emergence of targeted and combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview of cancer immunotherapies
Epidemiology
Spending on cancer
Cost of cancer treatment
Reimbursement policies
Economic burden of cancer
Orphan drug designation and regulatory approvals
PART 06: Pipeline portfolio
Anticipated number of products with single and multi-indications by 2020
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by type
Cancer monoclonal antibodies
Clinical trials of cancer monoclonal antibodies
Immune checkpoint inhibitors
Cancer vaccines
Non-specific immunotherapies
Global cancer monoclonal antibodies market
Global cancer vaccines market
Global immune checkpoint inhibitors market
Global non-specific immunotherapies market
PART 09: Geographical segmentation
Global cancer immunotherapies market by geography 2015-2020
Cancer immunotherapies market in Americas
Cancer immunotherapies market in EMEA
Cancer immunotherapies market in APAC
PART 10: Market drivers
Increase in prevalence of cancers
Increase in demand for cancer monoclonal antibodies
Patient assistance programs
Promising pipeline
PART 11: Impact of drivers
PART 12: Market challenges
Patent expiry of top-selling drugs
Poor diagnosis and screening
High developmental costs
Risk of side-effects
Stringent regulations
PART 13: Impact of drivers and challenges
PART 14: Market trends
Increase in cancer awareness
Emergence of targeted and combination therapies
Emergence of biosimilars
Strategic alliances
PART 15: Vendor landscape
Competitive scenario
Market share analysis 2015
Amgen
Bristol-Myers Squibb
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Takeda Pharmaceuticals1
Other prominent vendors
PART 16: Appendix
List of abbreviations
PART 17: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Cancer immunotherapies in global cancer drugs market
Exhibit 03: Global incidence of cancer by type 2015
Exhibit 04: Global mortality by cancer type 2015
Exhibit 05: Estimated numbers of male and female cancer survivors by age in US 2014
Exhibit 06: Spending on cancer by distribution channels 2013
Exhibit 07: Annual treatment cost per patient for cancer immunotherapies 2014
Exhibit 08: Average cost of surgeries associated with cancer ($ millions) 2014
Exhibit 09: National reimbursement of cancer drugs by countries 2014
Exhibit 10: US FDA Orphan drug designations and approvals for cancer immunotherapies
Exhibit 11: EU orphan drug designations and approvals for cancer immunotherapies
Exhibit 12: Key events in cancer immunotherapies, discovery, and approvals
Exhibit 13: Timeline of some cancer immunotherapies
Exhibit 14: Phase III pipeline molecules for global cancer monoclonal antibodies market
Exhibit 15: Phase II pipeline molecules for global cancer monoclonal antibodies market
Exhibit 16: Phase I pipeline molecules for global cancer monoclonal antibodies market
Exhibit 17: Pipeline molecules for global immune checkpoint inhibitors market
Exhibit 18: Phase III pipeline molecules for global cancer vaccines market
Exhibit 19: Near-launch immuno-oncology pipeline assets
Exhibit 20: Global cancer immunotherapies market 2015-2020 ($ billions)
Exhibit 21: Factors influencing global cancer immunotherapies market
Exhibit 22: Five forces analysis
Exhibit 23: Global cancer immunotherapies market by type 2015
Exhibit 24: Timeline for approvals of cancer monoclonal antibodies by US FDA
Exhibit 25: Clinical trials of cancer monoclonal antibodies by development phase
Exhibit 26: Status of clinical trials of cancer monoclonal antibodies
Exhibit 27: Global cancer immunotherapies market by type of cancer immunotherapies 2015
Exhibit 28: Global cancer immunotherapies market by type of cancer immunotherapies 2015-2020 ($ billions)
Exhibit 29: Global cancer monoclonal antibodies market 2015-2020 ($ billions)
Exhibit 30: Key drivers and challenges of global cancer monoclonal antibodies market
Exhibit 31: Global cancer vaccines market 2015-2020 ($ billions)
Exhibit 32: Global cancer vaccines market by application 2015
Exhibit 33: Key drivers and challenges of global cancer vaccines market
Exhibit 34: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 35: Key drivers and challenges for global immune checkpoint inhibitors market
Exhibit 36: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 37: Global cancer immunotherapies market by geography 2015
Exhibit 38: Global cancer immunotherapies market revenue by geography 2015-2020 ($ billions)
Exhibit 39: Cancer immunotherapies market in Americas 2015-2020 ($ billions)
Exhibit 40: Cancer immunotherapies market in EMEA 2015-2020 ($ billions)
Exhibit 41: Cancer immunotherapies market in APAC 2015-2020 ($ billions)
Exhibit 42: Global incidence of cancer 2015 and 2020 in millions
Exhibit 43: Impact of drivers
Exhibit 44: Patent expiries of major cancer monoclonal antibodies by 2020
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Expected combination regimen launches in oncology
Exhibit 47: Top cancer immunotherapies based on sales 2014 ($ billions)
Exhibit 48: YoY Sales comparison of top drugs 2011-2014 ($ billions)
Exhibit 49: Cancer immunotherapy companies by origin country
Exhibit 50: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2011-2014 ($ millions)
Exhibit 51: Amgen: YoY growth and revenue generated from net product sales of Prolia 2011-2014 ($ millions)
Exhibit 52: Amgen: YoY growth and revenue generated from net product sales of Vectibix worldwide excluding Japan 2011-2014 ($ millions)
Exhibit 53: Amgen: YoY growth and revenue of Vectibix in US 2012-2014 ($ millions)
Exhibit 54: Amgen: YoY growth and revenue of Vectibix in ROW 2012-2014 ($ millions)
Exhibit 55: Amgen: Key takeaways
Exhibit 56: Bristol-Myers Squibb: Segmentation by revenue 2014
Exhibit 57: Bristol-Myers Squibb: Revenue of oncology products by category 2014
Exhibit 58: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ millions)
Exhibit 59: Bristol-Myers Squibb: YoY growth and revenue of Erbitux in US, Canada, and Japan 2010-2014 ($ millions)
Exhibit 60: Bristol-Myers Squibb: Key takeaways
Exhibit 61: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of MabThera/Rituxan 2011-2014 ($ billions)
Exhibit 62: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2011-2014 ($ billions)
Exhibit 63: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2011-2014 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ billions)
Exhibit 65: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ billions)
Exhibit 66: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
Exhibit 67: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2012-2014 ($ millions)
Exhibit 68: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2014 ($ millions)
Exhibit 69: F. Hoffmann-La Roche: Key takeaways
Exhibit 70: GlaxoSmithKline: YOY growth and revenue of Arzerra 2012-2014 ($ millions)3
Exhibit 71: GlaxoSmithKline: YOY growth and revenue of Cervarix 2012-2014 ($ millions)3
Exhibit 72: GlaxoSmithKline: Key takeaways
Exhibit 73: Merck: YoY growth and revenue of Gardasil 2012-2014 ($ billions)6
Exhibit 74: Merck: YoY growth and revenue generated from net product sales of Erbitux, excluding US, Canada, and Japan 2011-2014 ($ billions
Exhibit 75: Merck: YOY growth and revenue of Erbitux in Europe 2012-2014 ($ millions)
Exhibit 76: Merck: YOY growth and revenue of Erbitux in emerging markets 2012-2014 ($ millions)
Exhibit 77: Merck: YOY growth and revenue of Erbitux in ROW 2012-2014 ($ millions)
Exhibit 78: Merck: Region-wise revenues of Erbitux 2012-2014 ($ millions)
Exhibit 79: Merck: Key takeaways
Exhibit 80: Takeda Pharmaceuticals: YoY growth and revenue generated from net product sales of Adcetris ($ millions)
Exhibit 81: Takeda Pharmaceuticals: YoY growth and revenue of Vectibix in Japan ($ millions)
Exhibit 82: Takeda Pharmaceuticals: Key takeaways